NCT00809549Unknown1 期
Granulocyte-Colony Stimulating Factor In Ischemic Stroke (GIST): A Pilot Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- A statistically significant increase in: mortality/ non-fatal grade III or greater adverse events measured by the NCI Common Toxicity Scale/ incidence of recurrent strokes/ worsening of neurological disabilities measured by standardized stroke scales.
研究概览
简要总结
- Circulating bone marrow and blood vessel precursors home in to sites of ischemia and aid regeneration of injured tissue
- Increasing the number of circulating precursors will improve in regeneration of damaged brain following ischemic stroke.
详细描述
We hypothesize that mobilization of bone marrow precursor cells into the blood stream will allow them to redistribute in the injured central nervous system and aid regeneration of damaged tissue. If the hypotheses is correct, it predicts that G-CSF treatment will improve the functional outcome of patients following acute ischemic stroke.
Underlying this work are the following considerations:
- Currently the clinical and functional outcomes following ischemic strokes are poor and require new treatment strategies.
- G-CSF administration is a well established routine treatment for the mobilization of hematopoietic and endothelial precursors from the bone marrow into the circulation.
- Acute ischemia locally increases factors that direct circulating bone marrow derived cells to home to these sites of injury.
- Evidence exists that bone marrow derived cells are able to repopulate different tissues including those of the CNS.
- Acute ischemic injury to the central nervous system provides a milieu for the regeneration of neural tissue.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 45 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is between 45 and 85 years of age
- •Patient is of either gender
- •The qualifying stroke is ischemic with a total NIH Stroke Score less than
- •The stroke involves the non-dominant hemisphere including the cerebral cortex and results in hemiparesis. The inclusion of sub-cortical strokes will be permitted if the size is of 3 cm or greater. Patients suffering strokes involving the dominant hemisphere resulting in mild dysphasia are also eligible.
- •The stroke is classified as a partial anterior cerebral syndrome by the Oxfordshire Criteria.
- •NIHSS at baseline evaluation with:
- •*Level of consciousness is not impaired as defined by an NIHSS between 0 and 1 on question 1a and
- •Hemiparesis as defined by
- •an NIHSS between 1 and 4 on questions 5 and/or
- •an NIHSS between 1 and 4 on questions
- •Be able to start the experimental treatment a minimum of 3 days and a maximum of 10 days after the initial presentation with the stroke,
- •Patient or surrogate gives informed consent,
- •The patient is fluent in either French or English.
排除标准
- •Patient with hemorrhagic stroke,
- •Patients with a pre-morbid modified Rankin score > 2 (Appendix 3b),
- •Patients with pre-morbid dementia by DSM-IV criteria.
- •Patients with a known allergic reaction to G-CSF or a component of G-CSF.
- •Patients with one or more significant co-morbidities expected to limit lifespan to less than 12 months. Examples include but are not limited to:
- •> CHF Class II NYHA
- •Known prior or ongoing malignancy except non-melanomatous skin cancer.
- •Acute or chronic infections (HIV, TB, etc.. )
- •Other significant cardiac, renal, hepatic or pulmonary dysfunction.
- •Patients with organ dysfunction that would preclude tests required for this study. Examples include but are not limited to:
- •*Serum Cr > 200 μmol/L that would prevent administration of contrast dye.
- •Patients with a known history of bone marrow dysfunction, such as myeloid leukemia or myeloproliferative state that would prevent treatment with G-CSF.
- •Patients with metal implants that would preclude MRI examination including but not limited to patients with
- •pacemakers,
- •ear implants, and
- •aneurysm brain clips.
- •Patients with:
- •a history compatible with a thrombophilic state or
- •with a pre-existing known thrombophilic state.
- •Patient unwilling or unable to comply with trial requirements.
- •Patients with an ongoing history of illicit drug use.
- •Female patients of child-bearing potential.
- •Patients exposed to other investigational drugs in the last 3 months.
- •Patients with known or suspected sickle cell disease,
- •Patients with splenic enlargement or an illness that results in splenic enlargement (For example, but not limited to myeloproliferative syndromes, hairy cell leukaemia, malaria, hepatic cirrhosis...),
- •Patients with an ongoing history of alcohol abuse,
- •Patients with a known or suspected history of allergy to intravenous contrast agents used for CT scans,
- •Patients that have received a chemotherapy agent within the previous 5 years (For example, but not limited to cyclophosphamide, anthracycline, methotrexate, fluorouracil...)
- •Patients that have received a therapy within the previous 5 years that interferes with hematopoiesis or circulating blood cells (For example, but not limited to Lithium, Campath....)
- •Patients that have received a cytokine within the last 6 months or are currently receiving a cytokine treatment (For example, but not limited to Erythropoietin, Granulocyte Macrophage Colony Stimulating Factor, Keratinocyte Growth Factor, Kit Ligand...)
研究组 & 干预措施
Normal Saline
Placebo Comparator
干预措施: Filgrastim (Drug)
Filgrastim
Experimental
干预措施: Filgrastim (Drug)
结局指标
主要结局
A statistically significant increase in: mortality/ non-fatal grade III or greater adverse events measured by the NCI Common Toxicity Scale/ incidence of recurrent strokes/ worsening of neurological disabilities measured by standardized stroke scales.
时间窗: 6 weeks, 3 months, 6 months and 12 months after the first dose of the study drug.
次要结局
- The secondary endpoints address the feasibility and efficacy of the study treatment: adequacy of bone marrow cell mobilization/ validation of imaging sequences/ Identification of optimal parameters for follow-up to be used in a subsequent larger trial.(6 weeks, 3 months, 6 months and 12 months after the first dose of the study drug.)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
G-CSF in Stimulating Peripheral Stem Cells for Autologous Stem Cell Transplant in Treating Patients With Chronic Phase Chronic Myeloid Leukemia in Complete RemissionLeukemiaNCT00233961Herbert Irving Comprehensive Cancer Center20
已完成
2 期
Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid LeukemiaLeukemiaNCT00011934Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
已完成
3 期
Granulocyte-Colony Stimulating Factor (G-CSF) as Optimizing Therapy for Pediatric Liver TransplantationSevere MalnutritionPELDUndernutritionLiver CirrhosisNCT04113317Fakultas Kedokteran Universitas Indonesia52
已完成
2 期
The Effect of GCSF in the Treatment of ALS PatientsAmyotrophic Lateral SclerosisNCT01825551Tehran University of Medical Sciences40
终止
3 期
STem cElls Mobilization in Acute Myocardial Infarction Outcome TrialAnterior Acute Myocardial InfarctionLeft Ventricular Systolic DysfunctionNCT01969890Heart Care Foundation532